Publications |
Author |
Reference |
MOA - Tumor Lysis |
Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors |
Villalona-Calero, M.A., et al. |
Cancer, 2016. 122(6): p. 875-83 |
The combination of intravenous REOLYSIN® and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer |
Mahalingam et al |
BMC Cancer (2015) 15:513 |
REOLYSIN® is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer |
Carew, J.S., et al |
Cell Death Dis, 2013. 4: p. e728 |
Intravenous administration of REOLYSIN®, a live replication competent RNA virus is safe in patients with advanced solid tumors |
Gollamudi, R., et al |
Invest New Drugs, 2010. 28(5): p. 641-9 |
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells |
Sei, S., et al |
Mol Cancer, 2009. 8: p. 47 |
Oncolytic viral therapy for human pancreatic cancer cells by reovirus |
Etoh, T., et al |
Clin Cancer Res, 2003. 9(3): p. 1218-23 |
Reovirus oncolysis of human breast cancer |
Norman, K.L., et al |
Hum Gene Ther, 2002. 13(5): p. 641-52 |
MOA - Immunity |
Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer |
Adel Samson |
BMJ Hepatology, 2016 |
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma |
Anne M Noonan |
Molecular Therapy vol. 24 no. 6 jun. 2016 1151 |
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses |
Rajani, K., et al |
Mol Ther, 2016. 24(1): p. 166-74 |
Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo |
El-Sherbiny, Y.M., et al |
Clin Exp Immunol, 2015. 180(1): p. 98-107 |
Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells |
Adair, R.A., et al |
Int J Cancer, 2013. 132(10): p. 2327-38 |
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients |
Adair, R.A., et al |
Sci Transl Med, 2012. 4(138): p. 138ra77 |
Oncolytic virus-initiated protective immunity against prostate cancer |
Gujar, S.A., et al |
Mol Ther, 2011. 19(4): p. 797-804 |
Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappaB mediated and supports innate and adaptive anti-tumor immune priming |
Steele, L., et al |
Mol Cancer, 2011. 10: p. 20 |
Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity |
Gujar, S.A., et al |
Mol Cancer Ther, 2010. 9(11): p. 2924-33 |
Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication |
Prestwich, R.J., et al |
Clin Cancer Res, 2009. 15(13): p. 4374-81 |
Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity |
Errington, F., et al |
The Journal of Immunology, 2008. 180(9): p. 6018-6026 |
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial |
White, C.L., et al |
Gene Ther, 2008. 15(12): p. 911-20 |